Skip to main content

Advertisement

SpringerLink
Log in

Adherence to oral endocrine treatments in women with breast cancer: can it be improved?

  • Review
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

There is a perception that women on oral endocrine treatments for oestrogen receptor-positive breast cancer will be adherent to these medicines, as they are facing a serious life-threatening disease, and the oral endocrine treatments are effective, easy to use and generally well tolerated. This is not in fact the case, and this is the basis of the first half of this review. The second half is of whether the changes/interventions to ‘improve’ adherence do actually increase adherence to the oral endocrine medicines. The review shows that better outcomes are achieved with good adherence to endocrine treatments in breast cancer. The rates of adherence to endocrine treatments range between 15 and 50%, and are influenced by a large number of factors (e.g. adverse effects, lack of belief in treatment, psychological problems and poor patient-health care provider relationship). Interventions to minimise the adverse effects have been used in an attempt to improve the adherence to the endocrine treatment therapies, but it is not known whether these do actually improve adherence. Similar, it has been assumed that interventions by health professionals (doctors, nurses and pharmacists) will improve the adherence, but this has not been tested. In conclusion, in women with breast cancer, we know there is a problem with adherence. There are also many approaches and suggestions about how to improve adherence to the oral endocrine treatments, but none of these approaches/suggestions have been scientifically tested, and they need to be.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wildiers H, Biganzoli L, Fracheboud J et al (2007) Management of breast cancer in elderly individuals: recommendations of the International Society of Geriatric Oncology. Lancet Oncol 8:1101–1115

    Article  PubMed  Google Scholar 

  2. Morris GJ, Naidu S, Topham AK et al (2007) Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution comparison compare with the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Cancer 110:876–884

    Article  PubMed  Google Scholar 

  3. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group, Forbes JF, Cuzick J, Buzdar A et al (2008) Effect of anastrozole and tamoxifen as adjuvant treatment of early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9:45–53

    Article  PubMed  Google Scholar 

  4. Hadji P (2010) Improving compliance and persistence to adjuvant tamoxifen and aromatase inhibitor therapy. Crit Rev Oncol Hematol 73:156–166

    Article  PubMed  Google Scholar 

  5. Fisher B, Constantino J, Redmond C et al (1989) A randomized clinical evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479–484

    Article  PubMed  CAS  Google Scholar 

  6. Fisher B, Dignam J, Bryant J et al (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529–1542

    Article  PubMed  CAS  Google Scholar 

  7. Fisher B, Jeong J-H, Bryant J et al (2004) Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet 364:858–868

    Article  PubMed  CAS  Google Scholar 

  8. McCowan C, Shearer J, Donnan PT et al (2008) Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer. Br J Cancer 99:1763–1768

    Article  PubMed  CAS  Google Scholar 

  9. Dezentjé VO, van Blijderveen NJ, Gelderblom H et al (2010) Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol 28:2423–2429

    Article  PubMed  Google Scholar 

  10. Baum M, Budzar AU, Cuzick J et al (2002) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359:2131–2139

    Article  PubMed  CAS  Google Scholar 

  11. Gross PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1791–1802

    Google Scholar 

  12. Breast International Group (BIG) 1-98 Collaborative Group, Thülimann B, Keshaviah A et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747–2757

    Article  Google Scholar 

  13. Coates AS, Keshaviah A, Thürlimann B et al (2007) Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25:486–492

    Article  PubMed  CAS  Google Scholar 

  14. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350:1081–1092

    Article  PubMed  CAS  Google Scholar 

  15. Coombes RC, Kilburn LS, Snowdon CF et al (2007) Survival and safety of exemestane versus tamoxifen after 2–3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369:559–570

    Article  PubMed  CAS  Google Scholar 

  16. van de Velde CJ, Rea D, Seynaeve C et al (2011) Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 377:321–331

    Article  PubMed  Google Scholar 

  17. Demissie S, Silliman RA, Lash TL (2001) Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol 19:322–328

    PubMed  CAS  Google Scholar 

  18. Partridge AH, Wang PS, Winer EP, Avorn J (2003) Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol 21:602–606

    Article  PubMed  CAS  Google Scholar 

  19. Fink AK, Gurwitz J, Rakowski W, Guadagnoli E, Silliman RA (2004) Patient beliefs and tamoxifen discontinuance in older women with estrogen receptor-positive breast cancer. J Clin Oncol 22:3309–3315

    Article  PubMed  Google Scholar 

  20. Lash TL, Fox MP, Westrup JL, Fink AK, Sillman RA (2006) Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat 99:215–220

    Article  PubMed  Google Scholar 

  21. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ (2007) Early discontinuation of tamoxifen: a lesson for oncologists. Cancer 109:832–839

    Article  PubMed  CAS  Google Scholar 

  22. Owusu C, Buist DS, Field TS et al (2008) Predictors of tamoxifen discontinuation among older women with estrogen receptor-positive breast cancer. J Clin Oncol 26:549–555

    Article  PubMed  Google Scholar 

  23. Partridge AH, LaFountain A, Mayer E et al (2008) Adherence to initial anastrozole therapy among women with early-stage breast cancer. J Clin Oncol 26:556–562

    Article  PubMed  CAS  Google Scholar 

  24. Ziller V, Kalder M, Albert US et al (2009) Adherence to adjuvant endocrine therapy in postmenopausal women with breast cancer. Ann Oncol 20:431–436

    Article  PubMed  CAS  Google Scholar 

  25. Hershman DL, Kushi LH, Shao T et al (2010) Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol 28:4120–4128

    Article  PubMed  Google Scholar 

  26. Crevellari D, Sun Z, Coates AS et al (2008) Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol 26:1972–1979

    Article  Google Scholar 

  27. Güth U, Huang DJ, Schötzau A et al (2008) Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99:428–433

    Article  PubMed  Google Scholar 

  28. Goldhirsch A, Wood WC, Gelber RD et al (2007) Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 18:1133–1144

    Article  PubMed  CAS  Google Scholar 

  29. Doggrell SA (2010) Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help. Drugs Aging 27:239–254

    Article  PubMed  Google Scholar 

  30. Hoskins JM, Carey LA, McLeod HL (2009) CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer 9:576–586

    Article  PubMed  CAS  Google Scholar 

  31. Schroth W, Goetz MP, Hamann U et al (2009) Association between CYP2D6 polymorphisms and outcomes among women with early breast cancer treated with tamoxifen. JAMA 302:1429–1436

    Article  PubMed  CAS  Google Scholar 

  32. Pal S (2011) CYP2D6 testing falls short as predictor of adjuvant tamoxifen efficacy. http://www.cancernetwork.com/conference-reports/sabcs2010/content/article/10165/1756542#. Accessed 5 May 2011

  33. Rae JM, Sikora MJ, Henry NL et al (2009) Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J 9:258–264

    Article  PubMed  CAS  Google Scholar 

  34. Kelly CM, Juurlink DN, Gomes T et al (2010) Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population bases cohort study. BMJ 340:C693

    Article  PubMed  Google Scholar 

  35. Sehdev S, Martin G, Sideris L, Lam W, Brisson S (2009) Safety of adjuvant endocrine therapies in hormone receptor-positive early breast cancer. Curr Oncol 16(Supplement 2):S14–S23

    PubMed  Google Scholar 

  36. Bertelli G, Hall E, Ireland E et al (2010) Long-term endometrial effects in postmenopausal women with early breast cancer participation in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continue tamoxifen after 2–3 years tamoxifen. Ann Oncol 21:498–505

    Article  PubMed  CAS  Google Scholar 

  37. Marsden J (2002) Hormone-replacement therapy and breast cancer. Lancet Oncol 3:303–311

    Article  PubMed  Google Scholar 

  38. Desmarais JE, Looper KJ (2010) Managing menopausal symptoms and depression in tamoxifen uses: implications of drug and medicinal interactions. Maturitas 67:296–308

    Article  PubMed  CAS  Google Scholar 

  39. Buijs C, Mon CH, Willesmse PH et al (2009) Venlafaxine versus clonidine for the treatment of hot flashes in breast cancer patients: a double-blind, randomized cross-over study. Breast Cancer Res Treat 115:573–580

    Article  PubMed  CAS  Google Scholar 

  40. Wengström Y (2008) Effectively nursing patients receiving aromatase inhibitor therapy. Breast 17:227–238

    Article  PubMed  Google Scholar 

  41. Carson JW, Carson KW, Porter LS, Keefe FJ, Seewaldt VL (2009) Yoga of Awareness program for menopausal symptoms in breast cancer survivors: results from a randomized trial. Support Care Cancer 17:1301–1309

    Article  PubMed  Google Scholar 

  42. Jacobson JS, Troxel AB, Evans J et al (2001) Randomized trial of black cohosh for the treatment of hot flashes among women with a history of breast cancer. J Clin Oncol 19:2739–2745

    PubMed  CAS  Google Scholar 

  43. Hervik J, Mjåland O (2009) Acupuncture for the treatment of hot flashes in breast cancer patients, a randomized, controlled trial. Breast Cancer Res Treat 116:311–316

    Article  PubMed  Google Scholar 

  44. Markopoulos G, Tzoracoleftherakis E, Polyschronis A et al (2010) Management of anastrozole-induced bone loss in breast cancer with oral risedronate: results from the ARBI prospective clinical trial. Breast Cancer Res 12:R24

    Article  PubMed  Google Scholar 

  45. Lester JE, Dodwell D, Purohit OP et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14:6336–6342

    Article  PubMed  CAS  Google Scholar 

  46. Penning-van Beest FJ, Goettsch WG, Erkens JA, Herrings RM (2006) Determinants of persistence with bisphosphonates—a study in women with postmenopausal osteoporosis. Clin Ther 28:236–242

    Article  PubMed  CAS  Google Scholar 

  47. McCombs JS, Thiebaud B, McLaughlin-Miley C, Shi J (2004) Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 48:271–287

    Article  PubMed  CAS  Google Scholar 

  48. Felson DT, Cummings SR (2005) Aromatase inhibitors and the syndrome of arthralgias with estrogen deprivation. Arthritis Rheum 52:2594–2598

    Article  PubMed  CAS  Google Scholar 

  49. Ingle JN, Schaid DJ, Goss PE et al (2010) Genome-wide associates and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol 10:4674–4682

    Article  Google Scholar 

  50. Mao JJ, Su HI, Feng R et al (2011) Association of functional polymorphisms in CYP19A1 with aromatase inhibitor associated arthralgia in breast cancer survivors. Breast Cancer Res 13:R8

    Article  PubMed  CAS  Google Scholar 

  51. Park IH, Lee Y-S, Lee KS et al (2011) Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes and adverse events associated with letrozole in patients with metastatic breast cancer. Cancer Chemother Pharmacol. doi:10.1007/s00280-011-1615-y

  52. Crew KD, Capodice JL, Greenlee H et al (2001) Randomized, blinded, sham-controlled trial of acupuncture for the management of aromatase inhibitor-associated joint symptoms in women with early-stage breast cancer. J Clin Oncol 28:1154–1160

    Article  Google Scholar 

  53. Xepapadakis G, Ntasiou P, Koronarchis D et al (2010) New views on treatment of aromatase inhibitor induced arthralgia. Breast 10:249–250

    Article  Google Scholar 

  54. Vattikuti NN, Ma C, Rastelli A et al (2010) High prevalence of low vitamin D and musculoskeletal complaints in women with breast cancer. Breast J 16:606–616

    Google Scholar 

  55. Prieto-Alhambra D, Javaid MK, Servitja S et al (2011) Vitamin D threshold to prevent aromatase inhibitor-induced arthralgia: a prospective cohort study. Breast Cancer Res Treat 125:869–878

    Article  PubMed  CAS  Google Scholar 

  56. Khan QJ, Reddy PS, Kimler BF et al (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119:111–118

    Article  PubMed  CAS  Google Scholar 

  57. Briot L, Tubiana-Hulin M, Bastit L, Kloos I, Roux C (2010) Effect of a switch of aromatase inhibitors on musculoskeletal symptoms in postmenopausal women with hormone-receptor-positive breast cancer: the ATOLL (articular tolerance of letrozole) study. Breast Cancer Res Treat 120:127–134

    Article  PubMed  CAS  Google Scholar 

  58. Switching to letrozole helps breast cancer patients with anastrozole-related rheumatologic symptoms. http://www.medicalnewstoday.com/articles/174943.php. Accessed 2 Nov 2010

  59. Davidson B, Vogel V, Wickerham L (2007) Oncologist-patient discussion of adjuvant hormonal therapy in breast cancer: results of a linguistic study focusing on adherence and persistence to therapy. J Support Oncol 5:139–143

    PubMed  Google Scholar 

  60. Hartigan K (2003) Patient education: the cornerstone of successful oral chemotherapy treatment. Clin J Oncol Nurs 6(Suppl):21–24

    Article  Google Scholar 

  61. Miaskowski C, Shockney L, Chlebowski RT (2008) Adherence to oral endocrine therapy for breast cancer: a nursing perspective. Clin J Oncol Nurs 12:213–221

    Article  PubMed  Google Scholar 

  62. Palmieri FM, Barton DL (2007) Challenges of oral medications in patients with advanced breast cancer. Semin Oncol Nurs 23(4 Suppl 2):S17–S22

    Article  PubMed  Google Scholar 

  63. Kelly A, Agius CR (2006) Improving adherence to endocrine therapies: the role of advanced practice nurses. Oncology 20(10 Suppl):50–54

    PubMed  Google Scholar 

  64. Presant CA, Bosserman L, Young T et al (2007) Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin Breast Cancer 10:775–778

    Article  Google Scholar 

  65. Barbour SY (2008) Caring for the treatment-experienced breast cancer patient: the pharmacist’s role. Am J Health Syst Pharm 65(10 Suppl 3):S16–S22

    Article  PubMed  CAS  Google Scholar 

  66. Patient’s anastrozole compliance to therapy programme (PACT). http://clinicaltrials.gov/ct2/show/NCT00555867. Accessed 2 Nov 2010

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Discipline of Medical Sciences, Faculty of Science and Technology, Queensland University of Technology, GPO2343, Brisbane, QLD, 4002, Australia

    Sheila A. Doggrell

Authors
  1. Sheila A. Doggrell
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sheila A. Doggrell.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Doggrell, S.A. Adherence to oral endocrine treatments in women with breast cancer: can it be improved?. Breast Cancer Res Treat 129, 299–308 (2011). https://doi.org/10.1007/s10549-011-1578-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-011-1578-z

Keywords

Search

Navigation